All In Biotech

Drug Trial Radar · NCT04719832

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype

Last checked: Nov 20, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 395 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

395

Actual

Start

Mar 17, 2021

Primary completion

Nov 21, 2023

Study completion Nov 21, 2023

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an eosinophilic phenotype

Conditions

  • Asthma

Interventions

  • GSK3511294 (Depemokimab)Biological

    GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.

  • PlaceboDrug

    Matching placebo will be administered as a normal saline using a pre-filled syringe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Clinically Significant Exacerbations up to 52 WeeksTime frame: Up to Week 52

Locations

123 sites in 12 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Encinitas, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Pasadena, California

  • GSK Investigational Site

    Rancho Cucamonga, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Loxahatchee Groves, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    New Port Richey, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Alpharetta, Georgia

  • GSK Investigational Site

    Calhoun, Georgia

  • GSK Investigational Site

    Columbus, Georgia

  • GSK Investigational Site

    Savannah, Georgia

  • GSK Investigational Site

    Normal, Illinois

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Owensboro, Kentucky

  • GSK Investigational Site

    Rochester Hills, Michigan

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Gastonia, North Carolina

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Boerne, Texas

  • GSK Investigational Site

    Cypress, Texas

  • GSK Investigational Site

    Cypress, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Kerrville, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Ajax, Ontario, Canada

  • GSK Investigational Site

    Niagara Falls, Ontario, Canada

  • GSK Investigational Site

    Ottawa, Ontario, Canada

  • GSK Investigational Site

    Windsor, Ontario, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Changchun, China

  • GSK Investigational Site

    Changchun, China

  • GSK Investigational Site

    Changsha, China

  • GSK Investigational Site

    Chengdu, China

  • GSK Investigational Site

    Guangzhou, China

Showing 40 of 123 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.